# Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

> **NCT07145229** · PHASE2 · RECRUITING · sponsor: **Atom Therapeutics Co., Ltd** · enrollment: 380 (estimated)

## Conditions studied

- Acute Gouty Arthritis
- Gout Flare
- Gout Flares
- Acute Gout Flare

## Interventions

- **DRUG:** ABP-745 Dose A
- **DRUG:** ABP-745 Dose B
- **DRUG:** Colchicine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07145229
- **Lead sponsor:** Atom Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-26
- **Primary completion:** 2026-05
- **Final completion:** 2026-06
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145229, "Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07145229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*